市場調査レポート
商品コード
1086915

慢性腎臓病(CKD)の疫学分析および予測:2021~2031年

Chronic Kidney Disease Epidemiology Analysis and Forecast, 2021-2031

出版日: | 発行: GlobalData | ページ情報: 英文 36 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
慢性腎臓病(CKD)の疫学分析および予測:2021~2031年
出版日: 2022年05月11日
発行: GlobalData
ページ情報: 英文 36 Pages
納期: 即納可能 即納可能とは
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の慢性腎臓病(CKD)の主要7市場(7MM:米国、フランス、ドイツ、イタリア、スペイン、英国、日本)において、CKDの総有病者数が2021年の1億3,48万5,844例から、2031年の1億1,435万1,930例へと増加し、予測期間中のAGRは1.05%になると予測されています。

当レポートでは、世界の慢性腎臓病(CKD)市場について調査分析し、7MMにおけるCKDのリスク要因、併存疾患、世界および過去の疫学動向をはじめ、CKDの疫学的予測に関する情報を提供しています。

目次

目次

第1章 慢性腎臓病:エグゼクティブサマリー

  • カタリスト
  • 関連レポート
  • 今後のレポート

第2章 疫学

  • 病気の背景
  • リスク要因と併存疾患
  • 世界および過去の動向
  • 7MM予測の調査手法
    • 情報源
    • 予測の前提条件と方法
    • CKDの総有病者数
    • CKDの総有病者数:ステージ別
    • CKDの診断をされた有病者数
    • CKDの診断をされた有病者数:ステージ別
    • CKDの診断をされた有病者数:透析依存性
  • CKDの疫学的予測(2021~2031年)
    • CKDの総有病者数
    • CKDの総有病者数:ステージ別
    • CKDの診断をされた有病者数
    • CKDの診断をされた有病者数:年齢別
    • CKDの診断をされた有病者数:性別
    • CKDの診断をされた有病者数:ステージ別
    • CKDの診断をされた有病者数:透析依存性別
  • 討論
    • 疫学予測の洞察
    • COVID-19の影響
    • 分析の限界
    • 分析の強み

第3章 付録

  • 参考文献
  • 著者について
    • 疫学者
    • レビュアー
    • 治療分析および疫学のグローバルディレクター
    • ヘルスケア事業・戦略のグローバルヘッドおよびEVP
  • お問い合わせ
図表

List of Tables

List of Tables

  • Table 1: Summary of updated data types
  • Table 2: KDIGO classification of CKD
  • Table 3: Risk factors and comorbid conditions associated with CKD

List of Figures

List of Figures

  • Figure 1: 7MM, total prevalent cases of CKD, both sexes, N, ages ≥18 years, 2021 and 2031
  • Figure 2: 7MM, diagnosed prevalent cases of CKD, both sexes, N, ages ≥18 years, 2021 and 2031
  • Figure 3: 7MM, diagnosed prevalence of CKD (%), men, ages ≥18 years, 2021
  • Figure 4: 7MM, sources used and not used to forecast the total and diagnosed prevalent cases of CKD
  • Figure 5: 7MM, sources used to forecast the total prevalent cases of CKD by stage
  • Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of CKD by stage
  • Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of CKD by dialysis dependence
  • Figure 8: 7MM, total prevalent cases of CKD, N, both sexes, ages ≥18 years, 2021
  • Figure 9: 7MM, total prevalent cases of CKD by stage, N, both sexes, ages ≥18 years, 2021
  • Figure 10: 7MM, diagnosed prevalent cases of CKD, N, both sexes, ages ≥18 years, 2021
  • Figure 11: 7MM, diagnosed prevalent cases of CKD by age group, N, both sexes, 2021
  • Figure 12: 7MM, diagnosed prevalent cases of CKD by sex, N, ages ≥18 years, 2021
  • Figure 13: 7MM, diagnosed prevalent cases of CKD by stage, N, both sexes, ages ≥18 years, 2021
  • Figure 14: 7MM, diagnosed prevalent cases of CKD by dialysis dependence, N, both sexes, ages ≥18 years, 2021
  • Figure 15: 7MM, diagnosed prevalent cases of CKD based on dialysis-dependent subtype, N, both sexes, ages ≥18 years, 2021
目次
Product Code: GDHCER294-22

Chronic kidney disease (CKD) (ICD-10 = N18) is a condition characterized by a gradual loss of kidney function over time. This leads to the accumulation of excess fluid and waste in the body. In the early stages, CKD is a largely asymptomatic condition. As the disease progresses, the symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2022). Advanced chronic kidney disease can cause dangerous levels of fluid, electrolytes, and wastes to build up in the body (Mayo Clinic, 2021). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease Improving Global Outcomes (KDIGO) classification system is considered to be the standard for GFR measurement and diagnosis of CKD (Levin et al., 2013). This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiology forecast for the total prevalent cases and diagnosed prevalent cases of CKD. The total and diagnosed prevalent cases of CKD are further segmented by age (18 years and older), sex, and stage (stage I, stage II, stage IIIa, stage IIIb, stage IV, and stage V) in these markets. Diagnosed prevalent cases of CKD are further segmented by dialysis-dependent (including both hemodialysis and peritoneal dialysis) and non-dialysis dependent. The following data describes epidemiology of CKD. In the 7MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of CKD from 103,485,844 cases of CKD in 2021 to 114,351,930 cases of CKD in 2031, with an AGR of 1.05% during the forecast period. The diagnosed prevalent cases of CKD in the 7MM are expected to increase from 18,135,434 cases in 2021 to 19,917,590 cases in 2030, with an AGR of 0.98% during the forecast period. Women accounted for more total and diagnosed prevalent cases of CKD than men in the 7MM and it predominantly affects older adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalData's forecast for the total and diagnosed prevalent cases for the 7MM.

Scope

  • The Chronic Kidney Disease (CKD) Epidemiology Report provides an overview of the risk factors and global trends of CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of CKD. The total and diagnosed prevalent cases of CKD are further segmented by age (18 years and older), sex, and stage (stage I, stage II, stage IIIa, stage IIIb, stage IV, and stage V) in these markets. Diagnosed prevalent cases of CKD are further segmented by dialysis-dependent (including both hemodialysis and peritoneal dialysis) and non-dialysis dependent. The model associated with the report also provides the diagnosed prevalent cases of CKD further segmented by hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases.
  • The CKD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Chronic Kidney Disease (CKD) Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CKD market.
  • Quantify patient populations in the global CKD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CKD therapeutics in each of the markets covered.
  • Understand magnitude of CKD population by subtype, digital vasculopathy, and other internal organ involvement.

Table of Contents

Table of Contents

1 Chronic Kidney Disease: Executive Summary

  • 1.1 Catalyst
  • 1.2 Related Reports
  • 1.3 Upcoming Reports

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
  • 2.4 7MM Forecast Methodology
    • 2.4.1 Sources
    • 2.4.2 Forecast Assumptions and Methods
    • 2.4.3 Total Prevalent Cases of CKD
    • 2.4.4 Total Prevalent Cases of CKD by Stage
    • 2.4.5 Diagnosed Prevalent Cases of CKD
    • 2.4.6 Diagnosed Prevalent Cases of CKD by Stage
    • 2.4.7 Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence
  • 2.5 Epidemiological Forecast for CKD (2021-31)
    • 2.5.1 Total Prevalent Cases of CKD
    • 2.5.2 Total Prevalent Cases of CKD by Stage
    • 2.5.3 Diagnosed Prevalent Cases of CKD
    • 2.5.4 Age-Specific Diagnosed Prevalent Cases of CKD
    • 2.5.5 Sex-Specific Diagnosed Prevalent Cases of CKD
    • 2.5.6 Diagnosed Prevalent Cases of CKD by Stage
    • 2.5.7 Diagnosed Prevalent Cases of CKD by Dialysis Dependence
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of the Analysis
    • 2.6.4 Strengths of the Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • Contact Us